WHO Report Compares Prices, IP Status Of HIV Treatment In Middle-Income Countries
A new report from the World Health Organization concludes that prices of HIV treatments vary greatly between middle-income countries (MICs), often depending on patent landscape, licensing agreements, whether drugs were sourced from originator companies, and regulatory approval. For third-line treatments, the price of drugs remains a challenge for all, with newer products more likely to be patented in key countries of production.
